BeiGene Ltd BGNE global phase 3 study RATIONALE 305 reached its primary endpoint overall survival with tislelizumab in combination with chemotherapy in patients with
Merck & Co Inc MRK announced results from the pivotal Phase 3 KEYNOTE-859 study of Keytruda (pembrolizumab) with fluoropyrimidine and platinum-based chemotherapy for gastric cancer.
The proportion of cancer-related deaths worldwide has increased significantly in recent years. The World Health Organization (WHO) estimates that more than 8 million people die
SYDNEY, Australia and FLORHAM PARK, NJ, November 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited IMUa clinical-stage immuno-oncology company, and Celularity Inc. CELU (Celularity), a clinical-stage
NEW YORK and SHANGHAI, Sept. 28, 2022 (GLOBE NEWSWIRE) — TH International Limited, the exclusive operator of Tim Hortons coffee shops in China (“Tims China”
Recovery after a serious car accident often takes weeks to months, while severe injuries may require a year or longer. The first 72 hours usually
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind
A groundbreaking new analysis from High Rise Financial highlights a severe and escalating crisis inside U.S. nursing homes, where tens of thousands of elderly residents